Overview
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients. Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications. Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired. Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.
Associated Conditions
- Acute Pulmonary Edema
- Ascites
- Body Fluid Retention
- Edema
- Hypertension
- Mild to Moderate Hypertension
- Chest congestion
Research Report
Furosemide (DB00695): A Comprehensive Clinical and Pharmacological Monograph
Drug Identification and Physicochemical Properties
Overview and Nomenclature
Furosemide is a potent, small-molecule loop diuretic that serves as a cornerstone in the management of fluid overload and hypertension.[1] Chemically classified as an anthranilic acid derivative, its primary therapeutic action is achieved through the inhibition of the sodium-potassium-chloride symporter (NKCC), a mechanism that places it in the class of NKCC inhibitors.[1] It is also categorized as an antihypertensive agent.[1]
The drug is universally recognized by its generic name, Furosemide, which is the recommended International Non-Proprietary Name (rINN).[5] An alternative name, Frusemide, was historically the British Approved Name and is still found in use in some regions.[3] Commercially, Furosemide is most famously known by the brand name Lasix, a name anecdotally derived from its typical duration of action, which "lasts six" hours.[1] Other notable brand names include Furoscix and Salix.[1] In major markets such as the United Kingdom and the United States, Furosemide is available by prescription only.[8]
Regulatory and Chemical Identifiers
To ensure unambiguous identification in clinical, research, and regulatory contexts, Furosemide is assigned a comprehensive set of identifiers. These standardized codes and names are essential for accurate data retrieval, reporting, and global pharmacovigilance.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/09/15 | Not Applicable | Completed | Bial - Portela C S.A. | ||
2025/09/11 | Not Applicable | ENROLLING_BY_INVITATION | |||
2025/04/23 | Phase 3 | Not yet recruiting | Stacy Johnson | ||
2025/03/27 | Phase 3 | Recruiting | |||
2025/03/27 | Phase 1 | Recruiting | |||
2025/02/12 | Early Phase 1 | ENROLLING_BY_INVITATION | |||
2025/01/22 | Not Applicable | ENROLLING_BY_INVITATION | |||
2024/07/17 | Phase 1 | Completed | |||
2024/06/21 | Not Applicable | Recruiting | National Aeronautics and Space Administration (NASA) | ||
2024/06/04 | Phase 4 | Not yet recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Baxter Healthcare Corporation | 36000-064 | INTRAVENOUS | 10 mg in 1 mL | 10/27/2018 | |
A-S Medication Solutions | 50090-6219 | ORAL | 20 mg in 1 1 | 7/14/2017 | |
Physicians Total Care, Inc. | 54868-2299 | INTRAVENOUS | 10 mg in 1 mL | 3/1/2012 | |
State of Florida DOH Central Pharmacy | 53808-0367 | ORAL | 20 mg in 1 1 | 6/2/2010 | |
RedPharm Drug, Inc. | 67296-0691 | ORAL | 20 mg in 1 1 | 1/13/2021 | |
Bryant Ranch Prepack | 63629-1120 | ORAL | 80 mg in 1 1 | 7/30/2020 | |
NorthStar Rx LLC | 72603-133 | INTRAVENOUS | 10 mg in 1 mL | 12/27/2022 | |
Sagent Pharmaceuticals | 25021-320 | INTRAVENOUS, INTRAMUSCULAR | 10 mg in 1 mL | 6/26/2025 | |
A-S Medication Solutions | 50090-2560 | ORAL | 20 mg in 1 1 | 6/28/2018 | |
Major Pharmaceuticals | 0904-7178 | ORAL | 40 mg in 1 1 | 12/30/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
APO-FUROSEMIDE TABLET 40 mg | SIN00088P | TABLET | 40 mg | 3/14/1988 | |
FUROSEMIDE-AFT SOLUTION FOR INJECTION 20MG/2ML | SIN16784P | INJECTION, SOLUTION | 20mg/2ml | 5/16/2023 | |
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 20 MG/2 ML | SIN15366P | INJECTION, SOLUTION | 20 mg/2 mL | 11/23/2017 | |
RASITOL TABLET 40MG | SIN14074P | TABLET | 40mg | 1/9/2012 | |
DIRINE INJECTION 20 mg/2 ml | ATLANTIC LABORATORIES CORPN LTD | SIN00239P | INJECTION | 20 mg/2 ml | 4/5/1988 |
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 50 MG/5 ML | SIN15365P | INJECTION, SOLUTION | 50 mg/5 mL | 11/23/2017 | |
FUSETIC SOLUTION FOR INJECTION 20MG/2ML | SIN16712P | INJECTION, SOLUTION | 20mg/2ml | 2/23/2023 | |
LASIX TABLET 40 mg | SIN00199P | TABLET | 40.00 mg | 3/28/1988 | |
FUROSEMIDE FRESENIUS KABI SOLUTION FOR INJECTION 20MG/2ML | SIN15131P | INJECTION, SOLUTION | 20mg/2ml | 12/7/2016 | |
FURMIDE TABLETS 40 mg | SIN00064P | TABLET | 40.00 mg | 2/24/1988 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
FUROSEMIDE TABLETS BP 40MG | N/A | N/A | N/A | 10/5/2020 | |
FUROSEMIDE-HAMELN SOLUTION FOR INJECTION 20MG/2ML | N/A | N/A | N/A | 5/27/2025 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
IP Furosemide furosemide (frusemide) 40 mg tablet bottle | 412881 | Medicine | A | 2/5/2024 | |
I-Furosemide furosemide (frusemide) 20 mg tablet bottle | 412876 | Medicine | A | 2/5/2024 | |
UREX furosemide (frusemide) 40 mg tablet blister pack | 34494 | Medicine | A | 1/17/1992 | |
FUROSEMIDE-BAXTER furosemide (frusemide) 20 mg/2 mL solution for injection ampoule | 148003 | Medicine | A | 4/3/2009 | |
Furosemide-WGR furosemide 40 mg tablet bottle | 186522 | Medicine | A | 6/28/2012 | |
IP Furosemide furosemide (frusemide) 20 mg tablet bottle | 412877 | Medicine | A | 2/5/2024 | |
FRUSIPCA furosemide (frusemide) 20 mg tablet bottle | 412874 | Medicine | A | 2/5/2024 | |
Furosemide-WGR furosemide 20 mg tablet bottle | 186524 | Medicine | A | 6/28/2012 | |
FRUSEMIX furosemide 40 mg tablet bottle | 186521 | Medicine | A | 6/28/2012 | |
LASIX furosemide 20mg/2mL injection ampoule | 12404 | Medicine | A | 8/1/1991 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
APO-FUROSEMIDE | 00707570 | Tablet - Oral | 80 MG | 12/31/1986 | |
NU-FUROSEMIDE TABLETS | nu-pharm inc | 02239226 | Tablet - Oral | 80 MG | N/A |
FUROSEMIDE INJECTION USP | hikma canada limited | 02384094 | Solution - Intravenous
,
Intramuscular | 20 MG / 2 ML | 8/22/2013 |
NU-FUROSEMIDE TABLETS | nu-pharm inc | 02239225 | Tablet - Oral | 40 MG | 3/19/2004 |
MINT-FUROSEMIDE | mint pharmaceuticals inc | 02466775 | Tablet - Oral | 80 MG | 7/30/2018 |
PMS-FUROSEMIDE | 02247493 | Tablet - Oral | 20 MG | 12/10/2003 | |
LASIX | sanofi-aventis canada inc | 02224690 | Tablet - Oral | 20 MG | 4/21/1997 |
FUROSEMIDE | sanis health inc | 02351420 | Tablet - Oral | 20 MG | 6/15/2010 |
BIO-FUROSEMIDE | biomed pharma | 02247371 | Tablet - Oral | 20 MG | 4/11/2003 |
LASIX SPECIAL TABLETS 500MG | hoechst roussel canada inc. | 01987615 | Tablet - Oral | 500 MG | 12/31/1994 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
FUROSEMIDA NORMON 40 MG COMPRIMIDOS EFG | Laboratorios Normon S.A. | 85062 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Not Commercialized |
FUROSEMIDA ALTAN 250mg/ 25ml SOLUCION PARA PERFUSION EFG | Altan Pharmaceuticals Sa | 68258 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
FUROSEMIDA SALA 20 mg/2 ml SOLUCION INYECTABLE EFG | Laboratorio Reig Jofre, S.A. | 65540 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
FUROSEMIDA BEXAL 40 mg COMPRIMIDOS EFG | Bexal Farmaceutica S.A. | 68078 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Not Commercialized |
FUROSEMIDA CINFA 40 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 64140 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
FUROSEMIDA UXA 40 MG COMPRIMIDOS EFG | Uxa Farma S.A. | 79029 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
FUROSEMIDA PHYSAN 20mg/2ml SOLUCIÓN INYECTABLE EFG | Laphysan S.A.U. | 62168 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Commercialized |
FUROSEMIDA TECNIGEN 40 MG COMPRIMIDOS EFG | Tecnimede España Industria Farmaceutica S.A. | 86391 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Not Commercialized |
FUROSEMIDA ALTAN 20mg/2ml SOLUCION INYECTABLE EFG | Altan Pharmaceuticals Sa | 68257 | SOLUCIÓN INYECTABLE | Uso Hospitalario | Not Commercialized |
FUROSEMIDA REIG JOFRE 20 mg/2 ml SOLUCION INYECTABLE EFG | Laboratorio Reig Jofre, S.A. | 65486 | SOLUCIÓN INYECTABLE | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.